CLINICAL TRIALS PROFILE FOR DEXAMETHASONE INTENSOL

All Clinical Trials for Dexamethasone Intensol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00098475 ↗	Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2004-10-26	This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
NCT00103285 ↗	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	2005-04-11	This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
NCT00103285 ↗	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	2005-04-11	This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Clinical Trial Conditions for Dexamethasone Intensol

Condition Name

Condition Name for Dexamethasone Intensol
Intervention	Trials
Recurrent Plasma Cell Myeloma	17
Acute Lymphoblastic Leukemia	15
Refractory Plasma Cell Myeloma	15
Untreated Adult Acute Lymphoblastic Leukemia	11

Condition MeSH

Condition MeSH for Dexamethasone Intensol
Intervention	Trials
Leukemia	33
Neoplasms, Plasma Cell	33
Multiple Myeloma	33
Leukemia, Lymphoid	31

Clinical Trial Locations for Dexamethasone Intensol

Trials by Country

Trials by Country for Dexamethasone Intensol
Location	Trials
Canada	104
Australia	57
New Zealand	24
Puerto Rico	12
Switzerland	6

Trials by US State

Trials by US State for Dexamethasone Intensol
Location	Trials
Texas	42
California	39
Minnesota	37
Georgia	31
Ohio	30

Clinical Trial Progress for Dexamethasone Intensol

Clinical Trial Phase

Clinical Trial Phase for Dexamethasone Intensol
Clinical Trial Phase	Trials
Phase 3	18
Phase 2/Phase 3	3
Phase 2	37

Clinical Trial Status

Clinical Trial Status for Dexamethasone Intensol
Clinical Trial Phase	Trials
Recruiting	42
Active, not recruiting	17
Not yet recruiting	15

Clinical Trial Sponsors for Dexamethasone Intensol

Sponsor Name

Sponsor Name for Dexamethasone Intensol
Sponsor	Trials
National Cancer Institute (NCI)	71
M.D. Anderson Cancer Center	17
Mayo Clinic	10

Sponsor Type

Sponsor Type for Dexamethasone Intensol
Sponsor	Trials
Other	72
NIH	71
Industry	20